# A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

> **NCT05091346** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 89 (actual)

## Conditions studied

- Melanoma
- Carcinoma, Hepatocellular
- Colorectal Neoplasms

## Interventions

- **DRUG:** E7386
- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05091346
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-27
- **Primary completion:** 2024-10-15
- **Final completion:** 2024-10-15
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05091346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05091346, "A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05091346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*